CA Patent

CA2761940C — Spray-dried pharmaceutical composition comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidaze[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea

Assigned to Ambit Bioscience Corp · Expires 2018-04-10 · 8y expired

What this patent protects

A spray-dried pharmaceutical composition comprising a dihydrochloride salt of the compound of Formula I, (see above formula) and hydroxypropyl-.beta.-cyclodextrin. The composition is useful for the treatment or management of proliferative diseases or FLT-3 mediated diseases.

USPTO Abstract

A spray-dried pharmaceutical composition comprising a dihydrochloride salt of the compound of Formula I, (see above formula) and hydroxypropyl-.beta.-cyclodextrin. The composition is useful for the treatment or management of proliferative diseases or FLT-3 mediated diseases.

Drugs covered by this patent

Patent Metadata

Patent number
CA2761940C
Jurisdiction
CA
Classification
—
Expires
2018-04-10
Drug substance claim
No
Drug product claim
No
Assignee
Ambit Bioscience Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.